FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

Nanobiotix’s Nanoparticle Radioenhancer Receives CE Mark

April 11, 2019
A A

Nanobiotix has earned the CE Mark for its Hensify radioenhancer, an injected nanoparticle device that amplifies the effectiveness of standard radiotherapy.

The device introduces a new mechanism of action that, in combination with radiotherapy, helps to physically eliminate tumors and kick a patient’s immune system into gear for local control and systemic disease treatment.

Hensify is an aqueous suspension of crystalline hafnium oxide nanoparticles that is injected into a tumor after initial radiotherapy treatment.

View today's stories